logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Partial Opioid Agonist class drugs

    FiltersReset Filters
    19 results

    • belbuca

      (buprenorphine hydrochloride)
      BioDelivery Sciences International Inc
      Usage: BELBUCA is indicated for the management of severe and persistent pain requiring long-term opioid treatment when alternative options are inadequate. It is not recommended for as-needed use and should be reserved for patients for whom other treatments have failed or are unsuitable.

    • brixadi

      (BUPRENORPHINE)
      Braeburn Inc.
      Usage: BRIXADI is indicated for treating moderate to severe opioid use disorder in patients who have started with a single dose of transmucosal buprenorphine or are already on buprenorphine. It should be used alongside a comprehensive treatment plan, including counseling and psychosocial support.

    • buprenorphine

      (BUPRENORPHINE)
      Rhodes Pharmaceuticals L.P.
      Usage: Buprenorphine Sublingual Tablets are indicated for treating opioid dependence, primarily during the induction phase, and should be used alongside a comprehensive treatment plan that includes counseling and psychosocial support.

    • buprenorphine

      (Buprenorphine)
      Sun Pharmaceutical Industries, Inc.
      Usage: Buprenorphine sublingual tablet is indicated for treating opioid dependence, preferred for induction. It should be part of a comprehensive treatment plan that includes counseling and psychosocial support.

    • buprenorphine

      (Buprenorphine)
      Actavis Pharma, Inc.
      Usage: Buprenorphine sublingual tablets are indicated for the treatment of opioid dependence, primarily for induction. They should be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.

    • buprenorphine and naloxone

      (Buprenorphine and Naloxone)
      Sun Pharmaceutical Industries, Inc.
      Usage: Buprenorphine and naloxone sublingual tablet is indicated for the maintenance treatment of opioid dependence. It should be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.

    • buprenorphine and naloxone

      (Buprenorphine and Naloxone)
      Rhodes Pharmaceuticals L.P.
      Usage: Buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence, and should be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.

    • buprenorphine and naloxone

      (Buprenorphine and Naloxone)
      Actavis Pharma, Inc.
      Usage: Buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence, and should be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.

    • buprenorphine and naloxone

      (Buprenorphine and Naloxone)
      Lannett Company, Inc.
      Usage: Buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence, to be used alongside a comprehensive treatment plan that includes counseling and psychosocial support.

    • buprenorphine hcl

      (Buprenorphine HCl)
      Hikma Pharmaceuticals USA Inc.
      Usage: Buprenorphine Sublingual Tablets are indicated for treating opioid dependence, primarily during the induction phase. They should be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.